Zobrazeno 1 - 10
of 1 157
pro vyhledávání: '"C Cappelli"'
Autor:
Shuming Chen, Tracee L. McMiller, Abha Soni, Farah Succaria, John-William Sidhom, Laura C. Cappelli, Livia A. Casciola-Rosen, Isaac R. Morales, Preethi Sankaran, Alan E. Berger, Julie Stein Deutsch, Qingfeng C. Zhu, Robert A. Anders, Jody E. Hooper, Drew M. Pardoll, Evan J. Lipson, Janis M. Taube, Suzanne L. Topalian
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional r
Externí odkaz:
https://doaj.org/article/44edc95deb6444eabbd3e50a4991237d
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 2, Pp 81-90 (2024)
Background Given that autoantibodies to peptidylarginine deiminase 4 (PAD4) are associated with erosive disease in established rheumatoid arthritis (RA), this study was conducted to compare the clinical and prognostic use of anti‐PAD4 antibodies in
Externí odkaz:
https://doaj.org/article/b845949a79f34d05af4ffaa6255e3db8
Autor:
Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest,
Externí odkaz:
https://doaj.org/article/0f9ad47d419c4ad4b3131ec90c49be9f
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1669-1681 (2023)
Abstract Introduction To understand factors leading to biologic switches and to develop a readily usable model with data collected in clinical care at preceding visits, with the overall aim to predict the probability of switching biologic at a subseq
Externí odkaz:
https://doaj.org/article/84e0bb69ef4b48c881765ade0f4e7f0d
Autor:
Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Läubli, David König, Eveline Daetwyler, Till Wallrabenstein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Immune checkpoint inhibitor (ICI) treatment has become an important therapeutic option for various cancer types. Although the treatment is effective, ICI can overstimulate the patient’s immune system, leading to potentially severe immune-related ad
Externí odkaz:
https://doaj.org/article/d27db90169b44153a99ca21f3faa5250
Autor:
Laura C Cappelli, Patrick M Forde, Ami A Shah, Julie Brahmer, Joseph C Murray, Paola Ghanem, Vincent K Lam, Benjamin P Levy, Kristen A Marrone, Susan C Scott, Josephine L Feliciano, Christine L Hann, David S Ettinger, Christopher Mecoli
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Purpose Concomitant autoimmune rheumatic diseases (ARD) can add morbidity and complicate treatment decisions for patients with lung cancer. We evaluated the tumour characteristics at diagnosis and clinical outcomes in lung cancer patients with or wit
Externí odkaz:
https://doaj.org/article/0a0d1f66575040e49d7c3c68700e07dc
Autor:
Laura C Cappelli, Maria E Suarez-Almazor, Michelle Turner, Stephane Champiat, Caroline Robert, Julie R Brahmer, Jarushka Naidoo, Jeffrey Weber, Joanne Riemer, Elad Sharon, Michael B Atkins, M Catherine Pietanza, Karthik Suresh, Catherine Murphy, Javid Moslehi, David Feltquate, Lee M Krug
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy may vary substantially in their clinical presentation, including natural history, outcomes to treatment, and patterns. The application of clinical guideli
Externí odkaz:
https://doaj.org/article/ce3651e8e8104a2ca8905bdbc8dd0dd4
Publikováno v:
Journal of Micropalaeontology, Vol 40, Pp 101-144 (2021)
We present a taxonomic revision of the family Fasciculithaceae focused on forms that characterize the early evolution of this family group, which are currently included within the genera Gomphiolithus, Diantholitha, Lithoptychius and Fasciculithus. T
Externí odkaz:
https://doaj.org/article/35952a4a062c47bbb7c73917098c2ad7
Autor:
Laura C Cappelli, Clifton O Bingham, Patrick M Forde, Evan J Lipson, Megan Schollenberger, Ami A Shah, Julie Brahmer, Valsamo Anagnostou, Erika Darrah, Jennifer Mammen
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objective Patients with inflammatory arthritis (IA) associated with immune checkpoint inhibitor (ICI) treatment for cancer are typically seronegative for anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor, but little is known ab
Externí odkaz:
https://doaj.org/article/aa475359aeb14e71bd548041dbec971e
Autor:
Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh
Publikováno v:
ACR Open Rheumatology, Vol 3, Iss 3, Pp 173-184 (2021)
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease
Externí odkaz:
https://doaj.org/article/619fc16b87424da49083d4b79c261367